<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. __)*
DRAXIS HEALTH INC.
- --------------------------------------------------------------------------------
(NAME OF ISSUER)
COMMON STOCK
- --------------------------------------------------------------------------------
(TITLE OF CLASS OF SECURITIES)
26150J 10 1
- --------------------------------------------------------------------------------
(CUSIP NUMBER)
ELAN INTERNATIONAL SERVICES, LTD.
C/O BROCK SILVERSTEIN LLC
800 THIRD AVENUE, 21ST FLOOR, NEW YORK, N.Y. 10022 (212) 371-2000
- --------------------------------------------------------------------------------
ATTENTION: DAVID ROBBINS, ESQ.
(NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED
TO RECEIVE NOTICES AND COMMUNICATIONS)
JULY 21, 1999
- --------------------------------------------------------------------------------
(DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of (Section)(Section) 240.13d-1(e), 240.13d-1(f) or
240.13d-1(g), check the following box. [ ]
Note: Schedules filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See (Section) 240.13d-7(b) for
other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 6
<PAGE>
SCHEDULE 13D
- --------------------------------------------------------------------------------
CUSIP NO. 26150J 10 1 PAGE 2 OF 6 PAGES
- --------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Elan International Services, Ltd.
- --------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(SEE INSTRUCTIONS) (a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3 SEC USE ONLY
- --------------------------------------------------------------------------------
4 SOURCE OF FUNDS (SEE INSTRUCTIONS)
WC
- --------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(D) OR 2(E) [ ]
- --------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
Bermuda
- --------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF 3,043,996 shares
SHARES
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH - 0 -
REPORTING -----------------------------------------------------------------
PERSON 9 SOLE DISPOSITIVE POWER
WITH 3,043,996 shares
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
- 0 -
- --------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,043,996 shares
- --------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)
EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- --------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
8.6% (based upon 32,280,524 shares of the Issuer
outstanding as of December 31, 1998, as set forth on
the Issuer's Annual Report on Form 20-F for the year
ended December 31, 1998)
- --------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- --------------------------------------------------------------------------------
<PAGE>
ITEM 1. SECURITY AND ISSUER.
Common Stock, no par value (the "Common Stock")
Draxis Health Inc.
6870 Goreway Drive
Mississauga, Ontario
Canada L4V 1P1
ITEM 2. IDENTITY AND BACKGROUND.
This Form 13-D is filed by Elan International Services, Ltd., a Bermuda
corporation ("EIS"), 102 St. James Court, Flatts, Smiths Parish, FL 04, Bermuda.
EIS is a wholly-owned subsidiary of Elan Corporation, plc, Lincoln House,
Lincoln Place, Dublin 2, Ireland, an Irish public limited company ("Elan").
During the last five years, none of the persons named above in this Item 2: (i)
has been convicted in a criminal proceeding (excluding traffic violations or
similar misdemeanors); or (ii) was a party to a civil proceeding of a judicial
or administrative body of competent jurisdiction, as a result of which
proceeding it was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, United
States federal or state securities laws, or finding any violation with respect
to such laws.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
On July 21, 1999, EIS acquired (a) 3,043,996 shares (the "Initial
Shares") of Common Stock of the Issuer for aggregate consideration of
$8,000,000.
ITEM 4. PURPOSE OF TRANSACTION.
EIS acquired the Securities for investment purposes.
Except as set forth above, neither EIS nor Elan has a plan or proposal
which relates to or would result in:
(a) The acquisition by any person of additional securities of the
Issuer, or the disposition of securities of the Issuer;
(b) An extraordinary corporate transaction such as a merger,
reorganization or liquidation involving the Issuer or any of its subsidiaries;
(c) A sale or transfer of a material amount of assets of the Issuer or
any of its subsidiaries;
(d) Any change in the present Board of Directors or management of the
Issuer, including any plans or proposals to change the number of or term of
Directors or to fill any existing vacancies on the Board;
(e) Any material change in the present capitalization or dividend
policy of the Issuer;
(f) Any other material change in the Issuer's business or corporate
structure;
(g) Changes in the Issuer's charter, by-laws, or instruments
corresponding thereto or other actions which may impede the acquisition of
control of the Issuer by any person;
(h) Causing the Common Stock to cease to be authorized to be traded on
the Nasdaq National Market System.
Page 3 of 6
<PAGE>
(i) To have the Common Stock terminated from registration under the
Securities Act of 1933; or
(j) Any action similar to any of those enumerated above.
ITEM 5. INTEREST IN THE SECURITIES OF THE ISSUER.
(a) 3,043,996 shares of Common Stock, representing 9.4% (based upon
32,280,524 shares of the Issuer outstanding as of December 31, 1998, as set
forth on the Issuer's Annual Report on Form 20-F for the year ended December 31,
1998).
(b) sole power to vote: 3,043,996 shares
shared power to vote: -0-
sole power to dispose: 3,043,996 shares
shared power to dispose: -0-
(c) None.
(d) None.
(e) Not Applicable.
ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT
TO SECURITIES OF THE ISSUER.
Not Applicable.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS.
1. Common Stock Purchase Agreement, dated July 21, 1999
Page 4 of 6
<PAGE>
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Date: August 13, 1999
Elan International Services, Ltd.
By: /s/ Kevin Insley
------------------------------
Kevin Insley
President
Page 5 of 6
<PAGE>
EXHIBIT INDEX
1. Common Stock Purchase Agreement, dated July 21, 1999.
Page 6 of 6
<PAGE>
EXHIBIT 1
COMMON STOCK PURCHASE AGREEMENT
-------------------------------
THIS COMMON STOCK PURCHASE AGREEMENT (the "Agreement") is entered into and
made effective as of June 17, 1999 (the "Effective Date") by and between Draxis
Health Inc., a Canada Business Corporations Act corporation with its principal
offices at 6870 Goreway Drive, Mississauga, Ontario, Canada L4V 1P1 (the
"Company"), and Elan International Services, Ltd., a Bermuda corporation with
its principal offices at 102 St. James Court, Flatts, Smiths, FL04, Bermuda (the
"Purchaser").
RECITALS
A. The Company and the Purchaser or its affiliate have entered into a
License, Distribution and Supply Agreement concurrently with this Agreement.
B. The Company and the Purchaser desire to enter into an agreement for the
purchase of common stock by Purchaser of Common Stock in the Company, and
related agreements, on the terms and conditions contained herein.
AGREEMENT
Now, therefore, the parties hereby agree as follows:
1. Sale of Common Stock. Subject to the terms and conditions of this
Agreement, the Purchaser hereby agrees to purchase, and the Company agrees to
sell to the Purchaser, three million forty three thousand nine hundred and
ninety six (3,043,996) shares of the Company's Common Stock (the "Shares") for a
purchase price equal to United States Dollars (US $2.6281) per share for an
aggregate purchase price of Eight Million United States Dollars (US
$8,000,000)(the "Purchase Price").
2. Closing. The purchase and sale of the Shares shall take place at the
offices of Elan Pharmaceuticals, Inc., on the date mutually agreed between the
parties (which time and place are designated as the "Closing"). At the Closing,
(i) the Company shall deliver to the Purchaser a certificate, registered in the
name of the Purchaser, representing the Shares to be purchased by the Purchaser
from the Company, dated as of the date of the Closing, against payment of the
Purchase Price therefor, (ii) the Purchaser shall deliver the Purchase Price by
check payable to the Company or by wire transfer of immediately available funds
to a bank account designated by the Company, and (iii) Douglas Parker, Director,
Legal Affairs, counsel to the Company with an opinion on US securities matters
by Gardner, Carton and Douglas, shall deliver to the Purchaser, an opinion,
dated as of the Closing, in substantially the form attached hereto as Exhibit A.
3. Obligations of the Company. Following the Closing and the issuance of the
Shares, the Company shall, at its own expense:
3.1 No later than February 1, 2000, prepare and file with the SEC a
shelf registration statement (the "Registration Statement") under Rule 415 of
the Securities Act of 1933 (the "Securities Act") with respect to such Shares
and use its reasonable best efforts to cause such Registration Statement to
become effective no later than June 15, 2000 (the "Effectiveness Date"). The
Company shall use its reasonable best efforts to continuously maintain the
effectiveness of such Registration Statement until the Shares have been sold in
1
<PAGE>
full, or the Shares may be sold without limitation under Rule 144 of the
Securities Act, whichever first occurs (the "Effectiveness Period"):
3.2 Prepare and file with the SEC such amendments, post-effective
amendments, prospectus and prospectus supplements to such Registration Statement
and the prospectus used in connection with such Registration Statement as may be
necessary to comply with the provisions of the Act with respect to the
disposition of all securities covered by such Registration Statement.
3.3 Furnish to Purchaser such numbers of copies of the Registration
Statement and the prospectus, including a preliminary prospectus, in conformity
with the requirements of the Securities Act, and such other documents as the
Purchaser may reasonably request in order in order to facilitate the disposition
of Shares covered by such Registration Statement.
3.4 Use its reasonable best efforts to register and qualify the Shares
covered by such Registration Statement under such other securities or Blue Sky
laws of such jurisdictions as shall be necessary or appropriate as reasonably
requested by Purchaser; or, in the case of any underwritten public offering, by
the managing underwriter, provided, that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such states or
jurisdictions.
3.5 In the event of any underwritten public offering (solely in the
Company's discretion), enter into and perform its obligations under an
underwriting agreement (including without limitation, indemnification by the
Company of the underwriter or underwriters, and a market stand-off agreement or
agreements by the Company and such officers, directors or other entities as a
managing underwriter reasonably requests, on similar terms and for the same
duration as provided in this Agreement as to Purchaser), in usual, reasonable
and customary form, with the managing underwriter of such offering. Purchaser
shall also enter into and perform its obligations under such an agreement;
provided, that such agreement shall not contain any provisions applicable to
Purchaser which are inconsistent with the provisions hereof.
3.6 Notify Purchaser at any time when a prospectus relating thereto is
required to be delivered under the Securities Act or the happening of any event
as a result of which the prospectus included in such Registration Statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading in the light of the circumstances then
existing.
3.7 Cause all such Shares registered pursuant to this Agreement to be
listed on each securities exchange on which the Common Stock is then listed,
which shall include Nasdaq and The Toronto Stock Exchange.
3.8 Provide a transfer agent and registrar for all Shares registered
hereunder and provide the Shares the same CUSIP number as the Common Stock, in
each case not later than the effective date of such registration.
3.9 Where the Company is pursuing registration of shares by an
underwritten public offering, use its reasonable best efforts to furnish, at the
request of Purchaser on the date that such Shares are delivered to the
underwriters for sale, copies of (i) an opinion, dated
2
<PAGE>
such date, of counsel representing the Company for the purposes of such
registration, in form and substance as is customarily given to underwriters in
the underwritten public offering, addressed to the underwriters, if any, and
(ii) a letter dated such date, from the independent certified public accountants
of the Company, in form and substance as is customarily given by independent
certified public accountants to the underwriters in an underwritten public
offering, addressed to the underwriters; if any.
3.10 Where the Company is pursuing registration of shares by an
underwritten public offering, make available for inspection by Purchaser, any
underwriter participating in any distribution and any attorney, accountant or
other agent retained by Purchaser or any underwriter, all financial and other
records, pertinent corporate documents and properties of the Company, and cause
the Company's officers, directors and employees to supply, all information
reasonably requested by Purchaser, in its capacity as selling stockholder, and
any such underwriter, attorney, accountant or agent in connection with such
registration statement.
4. Representations and Warranties of the Company. The Company hereby
represents and warrants to the Purchaser as follows:
4.1 Organization; Good Standing; Qualification. The Company is a
corporation duly organized, validly existing under the laws of Canada, and not
discontinued or dissolved, has all requisite corporate power, capacity and
authority to own and operate its properties and assets and to carry on its
business as now conducted, to execute and deliver this Agreement and that
certain License, Distribution and Supply Agreement, dated as of even date
herewith, between the Company and the Purchaser (the "License Agreement"), to
issue and sell the Shares, and to carry out the provisions of this Agreement and
the License Agreement. The Company is duly and currently qualified to do
business as a foreign corporation to transact business in each jurisdiction in
which the failure to do so would have a material adverse effect on its business
and properties.
4.2 Authorization. All corporate action on the part of the Company, its
officers, directors and shareholders necessary for the authorization, execution
and delivery of this Agreement and the License Agreement, the performance of all
obligations of the Company hereunder and thereunder at the Closing and the
authorization, Issuance, sale and delivery of the Shares being sold hereunder
has been taken or will be taken prior to the Closing, and this Agreement and the
License Agreement constitute valid and legally binding obligations of the
Company, enforceable in accordance with their respective terms, except (i) as
limited by applicable bankruptcy, insolvency, moratorium and other laws of
general application affecting enforcement of creditors' rights generally, (ii)
as limited by laws relating to the availability of specific performance,
injunctive relief or other equitable remedies, and (iii) to the extent the
indemnification provisions contained in this Agreement may be limited by
applicable federal, provincial or state securities law.
4.3 Valid Issuance of Common Stock. The Shares that are being purchased
by the Purchaser hereunder will upon issuance and delivery hereunder be duly and
validly issued, fully paid and nonassessable, and will be free of liens,
encumbrances and claims of any kind and of restrictions on transfer other than
restrictions on transfer under this Agreement and under applicable United States
state and federal securities laws and applicable Canadian securities regulatory
requirements.
4.4 Governmental Consents. No consent, approval, qualification, order
or authorization of, or filing with, any local, state, provincial or federal
governmental authority is
3
<PAGE>
required on the part of the Company in connection with the Company's valid
execution, delivery or performance of this Agreement and the License Agreement,
or the offer, sale or issuance of the Shares by the Company, other than such
filings as have been made prior to the Closing, except Form D or any notices of
sale required to be filed under applicable state securities or "Blue Sky" laws
and applicable Canadian securities regulatory requirements, which will be timely
filed within the applicable periods therefor.
4.5 Capitalization and Voting Rights. Immediately prior to the Closing,
the authorized capital of the Company consists of:
(a) Preferred stock. An unlimited number of Preferred Shares, none
of which are issued and outstanding and Employee Participation Shares, of which
2,000,000 have been issued, 975,000 of which have been designated and issued as
Series A Participation Shares, 550,000 of which have been designated and issued
as Series B Participation, and 475,000 of which have been designated and issued
as Series C Participation Shares, of which 587,000 Series A, 435,000 Series B
and 475,000 Series C are issued and outstanding. The rights and privileges and
preferences of Preferred Stock and Participation Shares are as stated in the
Certificate of Incorporation of the Company filed with the Corporations
Directorate as of January 1, 1999, a true and correct copy of which has been
provided to the Purchaser (the "Certificate").
(b) Common Stock. An unlimited number of shares of common stock
("Common Stock"), of which 32,516,743 shares are issued and outstanding.
(c) Except for instruments listed on Exhibit B hereto there are no
outstanding options, warrants, rights (including conversion of preemptive rights
and rights of first refusal) or agreements for the purchase or acquisition from
the Company of any shares of its capital stock. The Company is not a party or
subject to any agreement or understanding, and, to the best of the Company's
knowledge, there is no agreement or understanding between any persons that
affects or relates to the voting or giving of written consents with respect to
any security or the voting by a director of the Company.
4.6 Subsidiaries. The Company does not own or control, directly or
indirectly, any interest in any other corporation, association or other business
entity, except as indicated in Exhibit C attached. The Company is not a
participant in any material joint venture, partnership or similar arrangement,
except as disclosed in the Company's Form 20F.
4.7 Compliance with Other Instruments. The Company is not in violation
or default in any material respect of any provision of its Certificate, Bylaws
or in any material respect of any provision of, and no consent or approval of
any third party is required under, any mortgage, indenture, agreement,
instrument or contract to which it is a party or by which it is bound or, to the
best of its knowledge, of any federal, provincial or state judgment, order,
writ, decree, statute, rule or regulation applicable to the Company. The
execution, delivery and performance by the Company of this Agreement and the
License Agreement and the consummation of the transactions contemplated hereby
and thereby will not result in any such violation or be in material conflict
with or constitute, with or without the passage of time or giving of notice,
either a material default under any such provision or an event that results in
the creation of any material lien, charge or encumbrance upon any assets of the
Company or the suspension, revocation, impairment, forfeiture, or nonrenewal of
any material permit, license, authorization, or approval applicable to the
Company, its business or operations, or any of its assets or properties.
4
<PAGE>
4.8 LITIGATION. There is no action, suit, proceeding or investigation
pending or currently threatened in writing against the Company or any of its
affiliates, except as indicated in Exhibit D. The Company is not a party to, or
to the best of its knowledge, named in any order, writ, injunction, judgment or
decree of any court or government agency or instrumentality. There is no action,
suit or proceeding by the Company currently pending or threatened in writing, or
that the Company currently intends to initiate, except as indicated in
Exhibit D.
4.9 DISCLOSURE. The Company has provided the Purchaser with all the
information requested by the Purchaser in connection with its decision to
purchase the Shares. Neither this Agreement, the License Agreement, nor any
written statements or information or certificates filed with securities
regulatory authorities contains any untrue statement of a material fact or omits
to state a material fact necessary to make the statements herein or therein not
misleading.
4.10 OFFERING. Subject in part to the truth and accuracy of the
Purchaser's representations set forth in this Agreement, the offer, sale and
issuance of the Shares as contemplated by this Agreement are exempt from the
registration requirements of the Securities Act, and neither the Company nor any
authorized agent acting on its behalf will take any action hereafter that would
cause the loss of such exemption.
4.11 FINANCIAL STATEMENTS. The Company has delivered to the Purchaser
its audited financial statements (balance sheet and profit and loss statement,
statement of shareholders' equity and statement of changes in financial position
including notes thereto) at December 31, 1998 and for the fiscal year then ended
(the "Audited Financial Statements") and its unaudited financial statements
(balance sheet and profit and loss statement including notes thereto) as at and
for the three-month period ended March 31, 1999 (the "Unaudited Financial
Statements" and, collectively with the Audited Financial Statements, the
"Financial Statements"). The Financial Statements have been prepared in
accordance with generally accepted accounting principles applied on a consistent
basis throughout the periods indicated and with each other, except that the
Unaudited Financial Statements may not contain all footnotes required by
generally accepted accounting principles. The Financial Statements fairly
present the financial condition and operating results of the Company as of the
dates, and for the periods, indicated therein, subject to normal year-end audit
adjustments. Except as set forth in the Financial Statements, the Company has no
material liabilities, contingent or otherwise, other than (i) liabilities
incurred in the ordinary course of business subsequent to March 31, 1999 and
(ii) obligations under contracts and commitments incurred in the ordinary course
of business and not required under generally accepted accounting principles to
be reflected in the Financial Statements, which, in both cases, individually or
in the aggregate, are not material to the financial condition or operating
results of the Company, except that the Company will enter into a loan agreement
to finance part of the fee owing on closing of the License Agreement. Except as
disclosed in the Financial Statements and except for guarantees by subsidiaries
of the Company which may be given under the above mentioned loan agreement, the
Company is not a guarantor or indemnitor of any indebtedness of any other
person, firm or corporation. The Company maintains and will continue to maintain
a standard system of accounting established and administered in accordance with
generally accepted accounting principles.
4.12 ABSENCE OF MATERIAL CHANGES. To the best of the Company's
knowledge, since March 31, 1999 there has not been any event or condition of any
type that has materially
5
<PAGE>
and adversely affected the business, properties, prospects or financial
condition of the Company.
4.13 TAX RETURNS AND PAYMENTS. The Company has timely filed all tax
returns and tax reports as required by law. These tax returns and tax reports
are true and correct in all material respects. The Company has paid all taxes
and other assessments due or has made adequate provision for the payment of
taxes that have or may have become due or payment of any assessment received by
the Company, except those contested by it in good faith. To the best of the
company's knowledge, there are no material pending challenges to any tax filings
by any government authority.
5. REPRESENTATIONS AND WARRANTIES OF THE PURCHASER. The Purchaser hereby
represents and warrants to the Company as follows:
5.1 AUTHORIZATION. The Purchaser has the requisite legal power and
authority to enter into this Agreement and this Agreement when executed shall
constitute a valid and legally binding obligation of the Purchaser.
5.2 INVESTMENT INTENT. This Agreement is made with the Purchaser in
reliance upon its representation to the Company, which by its execution hereof
it confirms, that the Shares have been acquired with its own funds for
investment for an indefinite period for its own account, not as a nominee or
agent, and not with a view to the sale or distribution of any part thereof, and
that Purchaser has no present intention of selling, granting participation in,
or otherwise distributing the same; provided that the Purchaser reserves the
right to control disposition of the Shares subject to the terms of this
Agreement. By executing this Agreement, the Purchaser further represents that it
does not have any contract, undertaking, agreement or arrangement with any
person to sell, transfer, or grant participations, to such person or to any
third person, with respect to any of the Shares.
5.3 RELIANCE UPON THE PURCHASER'S REPRESENTATIONS. The Purchaser
understands that (i) the Shares are not registered under the Securities Act or
qualified under any state securities law, and (ii) the Shares are being issued
to the Purchaser on the ground that the sale provided for in this Agreement and
the issuance of securities hereunder is exempt from registration under the
Securities Act pursuant to Section 4(2) thereof and/or Regulation D promulgated
thereunder and from applicable state securities law, and (iii) the Company's
reliance on such exemptions is predicated on the Purchaser's representations set
forth herein. The Purchaser understands that these exemptions only exempt the
issuance of the Shares to the Purchaser and not any sale or other disposition of
the Shares or any interest therein by the Purchaser.
5.4 RESTRICTED SECURITIES. The Purchaser acknowledges that the Shares
are restricted securities under the Securities Act and may not be resold or
transferred unless the Shares are first registered under the Federal securities
laws or unless an exemption from such registration is available. In addition,
the Purchaser understands that any resale or transfer must comply with
applicable state securities laws.
5.5 RECEIPT OF INFORMATION. Without limiting the rights and remedies
available to it, the Purchaser acknowledges that it believes it has received all
the information it considers necessary or appropriate for deciding whether to
purchase the Shares and that it has had an opportunity to ask questions and
receive answers from the Company regarding the terms and conditions of the
offering of the Shares and the business, properties, prospects, and financial
6
<PAGE>
condition of the Company and to obtain additional information (to the extent the
Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify the accuracy of any information furnished
to Purchaser or to which Purchaser had access.
5.6 INVESTMENT EXPERIENCE. The Purchaser represents that it has such
knowledge and experience in financial and business matters as to be capable of
evaluating the merits and risks of its investment, has the ability to bear the
economic risks of its investment and has been furnished with and has had access
to all of the information it considers necessary or appropriate to evaluate the
risks and merits of an investment in the Shares, and it had an opportunity to
discuss the Company's business, management and financial affairs with the
Company's management. The Purchaser represents that it is an "accredited
investor" as defined in Regulation D promulgated under the Securities Act.
5.7 LIMITATIONS ON DISPOSITION. The Purchaser agrees that in no event
will it make a disposition of any of the Shares (other than a permitted transfer
under this Agreement), unless and until (i) it shall have notified the Company
in writing at least 5 business days in advance of the proposed disposition and
shall have furnished the Company with a statement of the circumstances
surrounding the proposed disposition, and (ii) it shall have furnished the
Company with an opinion of counsel knowledgeable in securities matters and
reasonably satisfactory to the Company and in customary form to the effect that
(a) such disposition will not require registration of such Shares under the
Securities Act, or (b) appropriate action necessary for compliance with the
Securities Act has been taken, or (iii) the Company shall have waived, expressly
and in writing, its rights under clauses (i) and (ii) of this subparagraph. The
opinion shall also indicate that the disposition is exempt from in compliance
with or qualified under all applicable state securities laws. The Company shall
be allowed, at its option, to participate in the disposition by designating a
broker responsible for completing such disposition at the Company's expense in
an orderly way over a reasonable time, as mutually agreed by the Company and the
Purchaser.
5.8 PUBLIC SALE. The Purchaser agrees not to make, without the prior
written consent of the Company, any public offering or sale of the Shares, even
if permitted to do so pursuant to Rule 144(k) promulgated under the Securities
Act, until the earlier of (i) the Effectiveness Date or (ii) one (1) year after
the date of this Agreement.
5.9 LEGENDS. All certificates representing the Shares shall contain the
following legends:
"THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED
STATES SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, TRANSFERRED,
ASSIGNED, PLEDGED OR HYPOTHECATED ABSENT ANY EFFECTIVE REGISTRATION THEREOF
UNDER SUCH ACT OR COMPLIANCE WITH RULE 144 PROMULGATED UNDER SUCH ACT, OR
UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL KNOWLEDGEABLE IN
SECURITIES MATTERS, SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH
REGISTRATION IS NOT REQUIRED. THE SHARES REPRESENTED BY THIS CERTIFICATE ARE
SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN COMMON STOCK PURCHASE
AGREMEENT, WHICH CONTAINS CERTAIN RESTRICTIONS ON TRANSFER, A COPY OF WHICH
PURCHASE AGREEMENT IS AVAILABLE FOR INSPECTION AT THE EXECUTIVE OFFICES OF
THE COMPANY."
7
<PAGE>
6. MARKET STAND-OFF AGREEMENT. Where the Company is pursuing an underwritten
offering, the Purchaser hereby agrees that, during the period or duration
specified by the Company and an underwriter of common stock or other securities
of the Company, following the effective date of a registration statement of the
Company filed under the Securities Act, it shall not, to the extent requested by
the Company and such underwriter, directly or indirectly sell, offer to sell,
contract to sell (including, without limitation, any short sale), grant any
option to purchase or otherwise transfer or dispose of (other than to donees who
agree to be similarly bound) any securities of the Company held by it at any
time during such period except common stock included in such registration;
provided, however, that:
(a) such agreement shall not exceed ninety (90) days for each such
registration statement of the Company which covers common stock (or other
securities) to be sold on its behalf to the public in an underwritten offering;
and
(b) such agreement shall not apply to permitted transfers under
Section 10.1.
In order to enforce the foregoing covenant, the Company may impose
stop-transfer instructions with respect to the Shares held by the Purchaser (and
the shares or securities of every other person subject to the foregoing
restriction) until the end of such period.
7. REGISTRATION RIGHTS.
7.1 COMPANY REGISTRATION. If the Company shall decide or take steps to
register any of its Common Stock or securities convertible to or exchangeable
for Common Stock, either for its own account or the account of a security
Purchaser, other than a registration relating solely to employee benefit plans,
or a registration relating solely to a Rule 145 transaction, or a registration
on any registration form which does not permit secondary sales, the Company
will:
(a) promptly give to the Purchaser written notice of each such
proposed offering; and
(b) use its reasonable best efforts to include in each such
registration (and any related qualification under blue sky laws or other
compliance), except as set forth in Section 7.2 below, and in any underwriting
involved, all the Shares specified in a written request or requests, made by the
Purchaser within twenty (20) days after the written notice from the Company
described in Section 7.1(a) above is effective. Such written request may specify
all or a part of the Shares for inclusion.
7.2 UNDERWRITING. If the registration of which the Company gives notice
is for a registered public offering involving an underwriting, the Company shall
so advise the Purchaser as a part of the written notice given pursuant to
Section 7.1(a). In such event the right of the purchaser to registration
pursuant to Section 7.1 shall be conditioned upon the Purchaser's participation
in such underwriting and the inclusion of the Shares in the underwriting to the
extent provided herein. The Purchaser, in proposing to distribute its Shares
through such underwriting, shall (together with the Company and the holders of
other securities of the Company distributing their securities through such
underwriting, enter into an underwriting agreement in customary form with the
representative of the underwriter or underwriters selected by the Company.
8
<PAGE>
Notwithstanding any other provision of this Section, if the
representative of the underwriters advises the Company in writing that marketing
factors require a limitation of the number of shares to be underwritten, the
representative may (subject to the limitations set forth below) exclude all of
the Shares from, or limit the number of Shares to be included in, the
registration and underwriting. The Company shall so advise the Purchaser, and
the number of shares of securities that are entitled to be included in the
registration and underwriting shall be allocated first to the Company for
securities being sold for its own account and thereafter as set forth in Section
7.9. If the Purchaser does not agree to the terms of any such underwriting, it
shall be excluded therefrom by written notice from the Company or the
underwriter. Any Shares or other securities excluded or withdrawn from such
underwriting shall be withdrawn from such registration.
7.3 Expenses of Registration. All Registration Expenses (as defined
below) incurred in connection with any registration, qualification or compliance
pursuant to Section 7.1 shall be borne by the Company. All Selling Expenses (as
defined below) relating to securities so registered shall be borne by the
Purchaser and the other holders of such securities pro rata on the basis of the
number of shares of securities so registered on their behalf. For purposes of
this Agreement, the term "Registration Expenses" shall mean all expenses
incurred in effecting any registration pursuant to this Agreement, including,
without limitation, all registration, qualification and filing fees, printing
expenses, escrow fees, fees and disbursements of counsel for the Company, fees
and disbursements of one counsel for the Purchasers of the securities so
registered in any registration, blue sky or equivalent fees and expenses,
expenses of any regular or special audits incident to or required by any such
registration, but shall not include Selling Expenses (but excluding the
compensation of regular employees of the Company, which shall be paid in any
event by the Company), and the term "Selling Expenses" shall mean all
underwriting discounts and selling commissions applicable to the sale of the
Shares and all fees and disbursements of counsel for the Purchaser (other than
the fees and disbursements of the one counsel included in Registration
Expenses).
7.4 Registration Procedures. In the case of each registration effected
by the Company pursuant to this Section, the Company will keep the Purchaser
advised in writing as to the initiation of each registration and as to the
completion thereof. At its expense, the Company will use its reasonable best
efforts to:
(a) Keep such registration effective for a period of one hundred
twenty (120) days or until the Purchaser has completed the distribution
described in the registration statement relating thereto, whichever first
occurs; provided, however, that such 120-day period shall be extended for a
period of time equal to the period the Purchaser refrains from selling any
securities included in such registration at the request of an underwriter of
Common Stock (or other securities) of the Company;
(b) Prepare and file with the SEC such amendments and supplements
to such registration statement and the prospectus used in connection with such
registration statement as may be necessary to comply with the provisions of the
Securities Act with respect to the disposition of all securities covered by such
registration statement;
(c) Furnish such number of prospectuses and other documents
incident thereto, including any preliminary prospectus or amendment of or
supplement to the prospectus, as the Purchaser from time to time may reasonably
request;
9
<PAGE>
(d) Notify the Purchaser if any Shares are covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act on the happening of any event
as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading or incomplete in the light of the
circumstances then existing, and at the request of any such seller, prepare and
furnish to such seller a reasonable number of copies of a supplement to or an
amendment of such prospectus as may be necessary so that, as thereafter
delivered to the purchasers of such shares, such prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading or
incomplete in the light of the circumstances then existing;
(e) Use all reasonable efforts to register and qualify the
securities covered by the registration statement under such other securities or
Blue Sky laws of such jurisdiction as shall be reasonably requested by the
Purchaser; provided, however, that the Company shall not be required in
connection therewith or as a condition thereto to qualify to do business or to
file a general consent to service of process in any such state or jurisdiction;
(f) Cause all such Shares registered pursuant hereunder to be
listed on each securities exchange on which similar securities issued by the
Company are then listed;
(g) Provide a transfer agent and registrar for all Shares
registered pursuant hereunder and a CUSIP number for all such Shares, in each
case not later than the effective date of such registration;
(h) Otherwise use its reasonable best efforts to comply with all
applicable rules and regulations of the SEC, and make available to its
securityholders, as soon as reasonably practicable, an earnings statement
covering the period of at least twelve (12) months, but not more than eighteen
(18) months, beginning with the first month after the effective date of the
Registration Statement, which earnings statement shall satisfy the provision of
Section 11(a) of the Securities Act; and
(i) In connection with any underwritten offering pursuant to a
registration statement filed pursuant to Section 7 hereof, the Company will
enter into an underwriting agreement reasonably necessary to effect the offer
and sale of Common Stock, provided such underwriting agreement contains
customary underwriting provisions and provided further that if the underwriter
so requests the underwriting agreement will contain customary contribution
provisions.
7.5 Indemnification.
(a) The Company will indemnify the Purchaser, each of its
officers, directors and partners, legal counsel and accountants and each person
controlling the Purchaser within the meaning of Section 15 of the Securities
Act, with respect to which registration, qualification or compliance has been
effected pursuant to this Section 7, against all expenses, claims, losses,
damages and liabilities (or actions, proceedings or settlements in respect
thereof) arising out of or based on any untrue statement (or alleged untrue
statement) of a material fact contained in any prospectus, offering circular or
other document (including any related registration statement, notification or
the like) incident to any such registration, qualification or compliance, or
based on any omission (or alleged omission) to state therein a
10
<PAGE>
material fact required to be stated therein or necessary to make the statements
therein not misleading, or any violation by the Company of the Securities Act or
any rule or regulation thereunder applicable to the Company and relating to
action or inaction required of the company in connection with any such
registration, qualification or compliance, and will reimburse each the
Purchaser, each of its officers, directors, partners, legal counsel and
accountants and each person controlling the Purchaser, for any legal and any
other expenses reasonably incurred in connection with investigating and
defending or settling any such claim, loss, damage, liability or action,
provided that the Company will not be liable in any such case to the extent that
any such claim, loss, damage, liability or expense arises out of or is based on
any untrue statement or omission based upon written information furnished to the
Company by the Purchaser and stated to be specifically for use therein, provided
that the indemnity agreement contained in this Section 7.5(a) shall not apply to
amounts paid in settlement of any such losses, claims, damages, liabilities (or
actions in respect thereof) if such settlement is effected without the consent
of the Company (which consent not to be unreasonably withheld).
(b) The Purchaser will, if the Shares held by it are included in
the securities as to which such registration, qualification or compliance is
being effected, indemnify the Company, each of its directors, officers, partner,
legal counsel and accountants and each underwriter, if any, of the Company's
securities covered by such a registration statement, each person who controls
the Company or such underwriter within the meaning of Section 15 of the
Securities Act, each other shareholder and each of their officers, directors and
partners, and each person controlling such other shareholder, against all
claims, losses, damages and liabilities (or actions in respect thereof) arising
out of or based on any untrue statement (or alleged untrue statement) of a
material fact contained in any such registration statement, prospectus, offering
circular or other document, or any omission (or alleged omission) to state
therein a material fact required to be stated therein or necessary to make the
statements therein not misleading, and will reimburse the Company and such other
shareholders, directors, officers, partners, legal counsel and accountants,
persons, underwriters or control persons for any legal or any other expenses
reasonably incurred in connection with investigating or defending any such
claim, loss, damage, liability or action, in each case to the extent, but only
to the extent, that such untrue statement (or alleged untrue statement) or
omission (or alleged omission) is made in such registration statement,
prospectus, offering circular or other document in reliance upon and in
conformity with written information furnished to the Company by the Purchaser
and stated specifically for use therein, provided, however, that the indemnity
agreement contained in this Section 7.5(b) shall not apply to amounts paid in
settlement of any such claims, losses, damages or liabilities (or actions in
respect thereof) if such settlement is effected without the consent of the
Purchaser (which consent shall not be unreasonably withheld).
(c) Each party entitled to indemnification under this Section 7.5
(the "Indemnified Party") shall give notice to the party required to provide
indemnification (the "Indemnifying Party") promptly after such Indemnified Party
has actual knowledge of any claim as to which indemnity may be sought, and shall
permit the Indemnifying Party to assume the defense of any such claim or any
litigation resulting therefrom, provided that counsel for the indemnifying
party, who shall conduct the defense of such claim or any litigation resulting
therefrom, shall be approved by the indemnified party (whose approval shall not
unreasonably be withheld), and the Indemnified Party may participate in such
defense at such party's expense, and provided further that the failure of any
Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Section 8, to the extent such
failure is not prejudicial. No Indemnifying Party, in the defense of any such
claim or litigation, shall, except with the consent of each Indemnified Party,
consent to entry of
11
<PAGE>
any judgment or enter into any settlement which does not include as an
unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all liability in respect to such claim or
litigation. Each indemnified party shall furnish such information regarding
itself or the claim in question as an Indemnifying Party may reasonably request
in writing and as shall be reasonably required in connection with defense of
such claim and litigation resulting therefrom.
(d) If the indemnification provided for in this Section 7.5 is
held by a court of competent jurisdiction to be unavailable to an Indemnified
Party with respect to any loss, liability, claim, damage or expense referred to
therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified
Party hereunder, shall contribute to the amount paid or payable by such
Indemnified Party hereunder, shall contribute to the amount paid or payable by
such Indemnified Party as a result of such loss, liability, claim, damage or
expense in such proportion as is appropriate to reflect the relative fault of
the Indemnifying Party on the one hand and of the Indemnified Party on the
other. In connection with the statements or omissions which resulted in such
loss, liability, claim damage or expense as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and the Indemnified
Party shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission to state a
material fact relates to information supplied by the Indemnifying Party or by
the Indemnified Party and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.
(e) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution (as are reasonable and customary)
contained in the underwriting agreement entered into in connection with the
underwritten public offering are in conflict with the foregoing provisions, the
provisions in the underwriting agreement shall control.
7.6 Information by Purchaser. The Purchaser shall furnish to the
Company such information regarding the Purchaser and distribution proposed by
the Purchaser as the Company may reasonably request in writing and as shall be
reasonably required in connection with any registration, qualification or
compliance referred to in this Section 7.
7.7 Rule 144 Reporting. With a view to making available the benefits of
certain rules and regulations of the SEC which may permit the sale of the Shares
to the public without registration, the Company agrees to use its reasonable
best efforts to:
(a) Make and keep public information available as those terms are
understood and defined in Rule 144 under the Securities Act, at all times;
(b) File with the SEC in a timely manner all reports and other
documents required of the Company under the Securities Act and the Exchange Act;
and
(c) So long as the Purchaser owns any Shares, furnish to the
Purchaser forthwith upon written request a written statement by the Company as
to its compliance with the reporting requirement of Rule 144, and of the
Securities Act and the Exchange Act, a copy of the most recent annual or
quarterly report of the Company, and such other reports and documents so filed
as the Purchaser may reasonably request in availing itself of any rule or
regulation of the SEC allowing the Purchaser to sell any such securities without
registration.
12
<PAGE>
7.8 TRANSFER OR ASSIGNMENT OF REGISTRATION RIGHTS. The rights to cause
the Company to register securities granted to the Purchaser by the Company under
Section 7.1 may be transferred or assigned by the Purchaser only to a transferee
or assignee of not less than one million Shares (as presently constituted and
subject to subsequent adjustments for stock splits, stock dividends, reverse
stock splits and the like), and only provided that the Company is given written
notice at the time of or within a reasonable time after said transfer or
assignment, stating the name and address of said transferee or assignee and
identifying the securities with respect to which such registration rights are
being transferred or assigned, and provided further that the transferee or
assignee of such rights assumes in writing the obligations of the Purchaser
under this Section 7.
7.9 ALLOCATION OF REGISTRATION OPPORTUNITIES. In any circumstance in
which all of the Shares and other shares of Common Stock of the Company
(including shares of Common Stock issued or issuable upon conversion of shares
of any currently unissued series of Preferred Stock of the Company) with
registration rights (the "Other Shares") requested to be included in a
registration on behalf of the Purchaser or other selling shareholders cannot be
so included as a result of limitations of the aggregate number of the Shares and
Other Shares which may be so included, the number of Shares and Other Shares to
be included shall be allocated among the Purchaser and other selling
shareholders requesting inclusion of shares pro rata on the basis of the number
of shares of Shares and Other Shares that would be held by the Purchaser and
other selling shareholders, assuming conversion; provided, however, that, so
that such allocation shall not operate to reduce the aggregate number of the
Shares and Other Shares to be included in such registration, if the Purchaser or
other selling shareholder does not request inclusion of the maximum number of
the Shares and Other Shares allocated to him, her or it pursuant to the
above-described procedure, the remaining portion of his, her or its allocation
shall be reallocated among the Purchaser and other selling shareholders whose
allocations did not satisfy their requests pro rata on the basis of the number
of the Shares and Other Shares that would be held by the Purchaser and other
selling shareholders, assuming conversion, and this procedure shall be repeated
until all of the Shares and Other Shares that may be included in the
registration on behalf of the Purchaser and other selling shareholders have been
so allocated.
7.10 DELAY OF REGISTRATION. The Purchaser shall not have any right to
take any action to restrain, enjoin, or otherwise delay any registration as the
result of any controversy that might arise with respect to the interpretation or
implementation of this Section.
7.11 TERMINATION OF REGISTRATION RIGHTS. The right of the Purchaser to
request inclusion in any registrations pursuant to Section 7.1 shall terminate
on the earlier of the date that all Shares held by the Purchaser (i) are sold in
accordance with Rule 144 or (ii) may be sold under Rule 144(k).
8. MISCELLANEOUS.
8.1 TRANSFER. All or any part of the Shares may be transferred or
assigned to a subsidiary or parent corporation or affiliate of the Purchaser as
defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended ("Rule
12b-2"), if written notice is provided to the Company within thirty (30) days of
the transfer or assignment and the assignee or transferee agrees in writing to
be subject to the terms hereof to the same extent as if it were an original
Purchaser hereunder; provided, however, that in the event the Purchaser
transfers or assigns the Shares to an affiliate under Rule 12b-2 whose primary
business involves the investment of
13
<PAGE>
capital, such affiliate may Transfer (as defined below) the Shares under the
following conditions:
(a) such affiliate may not Transfer any Shares held by it for a
period of one (1) year from the date of this Agreement; and
(b) such affiliate shall agree in writing that it will be subject
to the provisions of this Section and to the terms and conditions of this
Agreement.
For the purposes of this Section, "Transfer" means to, directly or
indirectly, sell, offer to sell, contract to sell (including without limitation,
any short sale), grant any option to purchase or otherwise transfer or dispose
of the Shares.
8.2 PUBLIC STATEMENTS. Neither the Company nor the Purchaser (including
its affiliates under Rule 12b-2) shall use the name of the other party or
otherwise disclose the substance or existence of the transactions contemplated
in this Agreement or the License Agreement in any public statement, prospectus,
annual report or press release or other public communication (collectively
"Public Statements") without the prior written approval of the other party,
which may not be unreasonably withheld or delayed; provided, however, that both
parties shall endeavor in good faith to give the other party a minimum of two
(2) business days to review such Public Statements; provided, further, that,
upon approval of any such Public Statement, both parties may disclose to third
parties the information contained in such Public Statement without the further
approval of the other; and provided, further, that if a party hereto does not
approve such Public Statement, either party may still use the name of the other
party in any Public Statement without the prior written approval of the other
party, if such party is advised by counsel that such disclosure is required to
comply with applicable law.
8.3 FURTHER ASSURANCES. Each of the parties hereby agrees to execute
and deliver such other documents and to take such further actions as may
reasonably be requested by the other party in order to consummate the
transactions contemplated herein or to carry out the intent of this Agreement.
8.4 NOTICES. Any notice required or permitted hereunder shall be given
in writing and shall be deemed effectively given upon personal delivery or two
business days (in the recipient's jurisdiction) after delivery to a recognized
express courier of international standing, with all charges and fees prepaid,
addressed to the other party hereto at its address hereinafter shown below its
signature or at such other address as such party may designate by advance
written notice to the other party hereto.
8.5 GOVERNING LAW. The parties hereto agree that all questions
pertaining to the validity, enforcement and interpretation of this Agreement
shall be determined in accordance with the laws of the State of Delaware,
without regard to its principles regarding choice of law. Each party agrees that
it shall comply in all material respects with laws of any applicable
jurisdiction (including without limitation the federal and provincial laws of
Canada) in the performance of its obligations under this Agreement.
8.6 SUCCESSORS AND ASSIGNS. Except as otherwise provided herein, the
terms and conditions of this Agreement shall inure to the benefit of the
successors and assigns of the Company and, subject to the restrictions on
transfer herein set forth, be binding upon the Purchaser and its successors and
assigns.
14
<PAGE>
8.7 AMENDMENTS AND WAIVERS. This Agreement and the License Agreement
represent the entire understanding of the parties with respect to the subject
matter hereof and thereof and supersedes all previous understandings, written or
oral. This Agreement may only be amended with the written consent of the parties
hereto, or the successors or assigns of the foregoing, and no oral waiver or
amendment shall be effective under any circumstances whatsoever.
8.8 COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be considered one and the same Agreement and
shall become effective when one or more counterparts have been signed by each of
the parties and delivered to the other party.
8.9 SEVERABLE PROVISIONS. The provisions of this Agreement are
severable, and if any one or more provisions may be determined to be judicially
unenforceable, in whole or in part, the remaining provisions shall nevertheless
be binding and enforceable.
[REMAINDER OF PAGE LEFT INTENTIONALLY BLANK]
15
<PAGE>
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the day and year first above written.
COMPANY: DRAXIS HEALTH INC.
By: /s/ Martin Barkin
---------------------------------
Name: Martin Barkin
Title: President and Chief
Executive Officer
Address: 6870 Goreway Drive
Mississauga, Ontario
Canada L4V 1P1
PURCHASER: ELAN INTERNATIONAL SERVICES, LTD.
By: /s/ Kevin Insley
---------------------------------
Name: Kevin Insley
Title: President & Chief
Financial Officer
Address: 102 St. James Court
Flatts, Smiths, FL04
Bermuda
16
<PAGE>
EXHIBIT A
LEGAL OPINION
Legal opinion from counsel reasonably acceptable to Purchaser to be delivered at
Closing, along with delivery of Shares. Opinion will cover, among any other
topics (subject to customary assumptions and limitations):
1. Due incorporation, valid existence and good standing of Company
2. Requisite corporate authority to enter into and perform Agreement; duly
executed and delivered; legal, valid and binding obligation of Company
enforceable according to its terms
3. Shares are validly issued, fully paid and nonassessable, free and clear of
all liens, encumbrances or restrictions of any kind except per Agreement and
applicable securities laws
4. Capitalization of Company, per Agreement
5. Execution, delivery and performance of Agreement do not violate applicable
law or constitute default or breach of any obligation or agreement of
company, its charter documents or any order binding Company
6. No claim, litigation or proceeding pending or threatened in writing which
would question the validity or right to enter into the Agreement or its
performance by Company
7. Offer and sale of the Shares are exempt from registration requirements of the
Securities Act and from applicable Blue Sky laws
17
<PAGE>
EXHIBIT B
WARRANTS, OPTIONS, AND CONVERTIBLE SECURITIES
As of June 17, 1999, there were no warrants, options or securities convertible
into common shares of Draxis Health Inc. other than the following:
1. 500,000 warrants issued to Novopharm Limited to purchase one common share
per warrant at CDN$2.09 per share on or before April 18, 2000;
2. 600,000 warrants issued to Royal Bank Capital Corporation to purchase one
common share per warrant at CDN$3.70 per share on or before July 31, 2000.
3. 3,046,867 option to purchase common shares under the Corporation's Stock
Option Plan at exercise prices ranging from US$1.48 to CDN$4.42 expiring
from 1999 to 2006.
4. 2,000,000 participation shares convertible, in the case of Series A until
February 16, 2000, in the case of series B until December 18, 2000, and, in
the case of Series C until May 11, 2004.
18
<PAGE>
DRAXIS HEALTH INC.
CORPORATE ORGANIZATION CHART
(AS AT MAY 18, 1999)(1)
------------------
DRAXIS HEALTH INC.
(CANADA)
------------------
Canadian Companies
------------------------------------------------
Draximage Draxis Draxis
Inc. Pharms Pharmaceutical
Inc. Inc.
(Canada) (Canada) (Canada)
International Companies
-------------------------------------------------
DAHI DAHI DAHI
Animal Animal Animal
Health Health Health
(Australia) (New Zealand) (U.K.)
Pty Limited Pty Limited Limited
(Australia) (New Zealand) (England)
U.S. Companies
-----------------------------------------------------------
Deprenyl DAHI LLC DAHI Draxis
Animal Nevada U.S. Inc.
Health, Inc.
Inc.
(Los Angeles) (Delaware) (Nevada) (Delaware)
1 All companies are 100% owned
<PAGE>
EXHIBIT D
On March 12, 1998, Dr. Jozsef Knoll issued a Notice of Action against
the Corporation and DAHI (the "Defendants"). A formal Statement of Claim was
filed with the Ontario Court (General Division) on May 1, 1998. Dr. Knoll is
claiming damages principally in resepct of a royalty based on the net profit
from sales of Anipryl (Registered Trademark) which he claims he is owed based on
a December 1990 consulting agreement between himself and DAHI (the "Consulting
Agreement"). Pursuant to the Statement of Claim, Dr. Knoll is also seeking
relief under the oppression remedy contained in Section 241 of the Canada
Business Corporations Act, claiming that the failure of the Defendants to abide
by the terms of the Consulting Agreement has been oppressive and has unfairly
disregarded his interests.
The Corporation continues to regard all of Dr. Knoll's claims to be
entirely without merit. The Corporation has retained counsel and is defending
vigorously the lawsuit.
On August 6, 1998, the Corporation issued a Statement of Claim against
Dr. Morton P. Shulman claiming damages in the amount of $1,500,000 for breach of
contract, confidence and breach of fiduciary duty and damages for defamation,
injurious falsehood, intimidation and intentional interference with economic and
contractual relations (the "Claim"). The Corporation has been advised by the
solicitors for Dr. Shulman that the Public Trustee for the Province of Ontario
has taken over the affairs of Dr. Shulman and they have been advised not to take
instructions from Dr. Shulman or take any steps in any litigation involving him
without further instruction from the Public Trustee. To date, neither the
Corporation nor its solicitors have received any further correspondence from Dr.
Shulman's solicitors with respect to the Claim.
On April 11, 1996, the contract marketing organization used by Draxis
in the Unites States and one of its employees were sued in the State of New
York. Three individuals have claimed that the failure by that organization to
hire two of the plaintiffs and the termination of the employment of the third
plaintiff amounted to unlawful discriminatory hiring or termination practices in
violation of New York law. A consultant under contract with Draxis has also been
sued. Draxis and Draxis U.S. Inc. have been sued based on the consultant's
alleged conduct. Each of the plaintiffs is seeking US$5,000,000 in damages.
Draxis has retained counsel and has instructed such counsel to vigorously defend
the claim. Based on information made available to the Company to date, Draxis
does not believe that this litigation will have a material adverse effect on its
results of operations or financial condition.
